BR112022025647A2 - Proteínas quiméricas de rsv e coronavírus, composições imunogênicas e métodos de uso - Google Patents

Proteínas quiméricas de rsv e coronavírus, composições imunogênicas e métodos de uso

Info

Publication number
BR112022025647A2
BR112022025647A2 BR112022025647A BR112022025647A BR112022025647A2 BR 112022025647 A2 BR112022025647 A2 BR 112022025647A2 BR 112022025647 A BR112022025647 A BR 112022025647A BR 112022025647 A BR112022025647 A BR 112022025647A BR 112022025647 A2 BR112022025647 A2 BR 112022025647A2
Authority
BR
Brazil
Prior art keywords
coronavirus
rsv
methods
immunogenic compositions
chimeric proteins
Prior art date
Application number
BR112022025647A
Other languages
English (en)
Inventor
Moore Martin
Jordan Robert
Tioni Mariana
Original Assignee
Meissa Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meissa Vaccines Inc filed Critical Meissa Vaccines Inc
Publication of BR112022025647A2 publication Critical patent/BR112022025647A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

PROTEÍNAS QUIMÉRICAS DE RSV E CORONAVÍRUS, COMPOSIÇÕES IMUNOGÊNICAS E MÉTODOS DE USO. A invenção refere-se geralmente a proteínas de fusão virais quiméricas compreendendo o ectodomínio e, opcionalmente, o domínio transmembranar de uma primeira proteína de fusão viral (por exemplo, uma proteína spike de um coronavírus) e o domínio citoplasmático de uma segunda proteína de fusão viral (por exemplo, RSV), composições imunogênicas compreendendo tais proteínas quiméricas e métodos de uso das mesmas.
BR112022025647A 2020-06-17 2021-06-17 Proteínas quiméricas de rsv e coronavírus, composições imunogênicas e métodos de uso BR112022025647A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063040193P 2020-06-17 2020-06-17
US202163160445P 2021-03-12 2021-03-12
US202163194092P 2021-05-27 2021-05-27
PCT/US2021/037846 WO2021257841A1 (en) 2020-06-17 2021-06-17 Chimeric rsv and coronavirus proteins, immunogenic compositions, and methods of use

Publications (1)

Publication Number Publication Date
BR112022025647A2 true BR112022025647A2 (pt) 2023-03-07

Family

ID=79268419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025647A BR112022025647A2 (pt) 2020-06-17 2021-06-17 Proteínas quiméricas de rsv e coronavírus, composições imunogênicas e métodos de uso

Country Status (10)

Country Link
US (1) US20230248815A1 (pt)
EP (1) EP4168045A1 (pt)
JP (1) JP2023530445A (pt)
KR (1) KR20230038205A (pt)
AU (1) AU2021292397A1 (pt)
BR (1) BR112022025647A2 (pt)
CA (1) CA3187161A1 (pt)
MX (1) MX2022016502A (pt)
TW (1) TW202208399A (pt)
WO (1) WO2021257841A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092100A2 (en) * 2021-11-19 2023-05-25 Meissa Vaccines, Inc. Methods of administering chimeric vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012489A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Avian influenza chimeric vlps
KR20110074563A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
WO2010148434A1 (en) * 2009-06-22 2010-12-29 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Chimeric molecules
CN111218459B (zh) * 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Also Published As

Publication number Publication date
AU2021292397A1 (en) 2023-02-02
JP2023530445A (ja) 2023-07-18
EP4168045A1 (en) 2023-04-26
CA3187161A1 (en) 2021-12-23
US20230248815A1 (en) 2023-08-10
KR20230038205A (ko) 2023-03-17
WO2021257841A1 (en) 2021-12-23
MX2022016502A (es) 2023-03-13
WO2021257841A9 (en) 2022-02-24
TW202208399A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
EA200801501A1 (ru) Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
WO2021243122A8 (en) Engineered coronavirus spike (s) protein and methods of use thereof
PH12017500042A1 (en) Interleukin-2/interleukin-2-receptor alpha fusion proteins and methods of use
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
RU2017145074A (ru) Клетка
UA120917C2 (uk) Химерний білок фактора viii та його застосування
EA202092316A1 (ru) Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
SG169996A1 (en) Antiviral agents and vaccines against influenza
ZA200603731B (en) Plasmid system for multiple expression
NO20050083L (no) Ghrelin analoger
CL2010001569A1 (es) Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro.
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
ATE472334T1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
EA202191622A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
DK0929547T3 (da) Benzamidinderivater substitueret af cykliske aminosyrederivater eller cykliske hydroxysyrederivater og deres anvendelse som antikoagulantia
WO2021030153A3 (en) Engineered t cell receptors and uses thereof
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112022025647A2 (pt) Proteínas quiméricas de rsv e coronavírus, composições imunogênicas e métodos de uso
AR056245A1 (es) Membranas virales reconstituidas funcionales que contienen un coadyuvante
MX2022013934A (es) Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
WO2023056351A3 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
WO2018175740A8 (en) Anti-tmeff1 antibodies and antibody drug conjugates